COVID-19 / Biodefense Initiative

Heat Biologics COVID-19 / Biodefense Initiative

Our proprietary gp96 platform activates the human immune system to combat infectious diseases. Collaborators of Heat Biologics’ have laid a good foundation on engineering different pathogenic antigens into our platform. Previous preclinical studies using gp96 platform includes SIV/HIV, malaria and zika. The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020.

Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform. Such design has the potential of generating long-term immune responses and may confer immunity to different coronaviruses.


About Coronavirus

COVID-19 is caused by a new kind of coronavirus (SARS-CoV-2) that first emerged in December 2019. Coronavirus is an RNA-enveloped virus (70-120 nm in diameter) surrounded by characteristics spike-shaped proteins to mediate the attachment and entry into the cell.

Program Mechanism of Action
Indication Preclinical Phase 1 Phase 2 Phase 3

COVID-19 / Biodefense Initiative

(Cell Therapy)
Infectious Disease
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started